The highest NAFLD prevalence among T2D patients was observed in Eastern Europe (n=11 studies, 78.95%, 73.90-83.25%), followed by Middle East (n=15, 69.83%, 60.67-77.86%), Western Europe (n=19, 68.52%, 63.75-72.92%), USA & Australia (n=14, 63.82%, 50.75-75.12%), South Asia (n=24, 62.61%, 55.09-69.58%), East Asia (n=17, 60.89%, 56.26-65.33%), Asia Pacific (n=10, 51.56%, 38.83-64.08), Latin America (n=6, 51.35, 38.83-64.08%), and Africa (n=6, 43.05%, 20.82-68.49%)
According to some studies in a 2019 research review, Conversely, having diabetes Authors of a 2024 review of GLP-1 analogs in inflammatory arthritis and psoriasis gathered the research to date in these conditions
MDWatch also offers the Medicare GLP-1 Bridge Program FDA-approved GLP-1s for as little as a $50 copay, if you qualify
No, semaglutide does not damage your metabolism